Zyngenia promotes David Hilbert and appoints Daniel Menichella
This article was originally published in Scrip
Zyngenia, a biopharmaceutical company developing the next generation of antibody-based drugs, has promoted Dr David Hilbert to CSO and appointed Daniel Menichella CBO. Dr Hilbert joined Zyngenia in October 2009 as vice-president of research and development. Mr Menichella was previously senior vice-president of corporate development and strategy at Talecris Biotherapeutics.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.